Hjem › Leverkreft (hepatocellulært karcinom) › Missouri
Kliniske studier for Leverkreft (hepatocellulært karcinom) i Missouri
14 studier for Leverkreft (hepatocellulært karcinom) søker deltakere på steder i Missouri.
Byer i Missouri
Offisiell studietekst (engelsk)
The Vanguard Study: Testing a New Way to Screen for Cancer
- Saint Luke's Hospital of Kansas City, Kansas City
- Washington University School of Medicine, St Louis
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 45 til 75 · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06995898Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
- Research Facility, St Louis
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06726161Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Siteman Cancer Center - St. Peters, City of Saint Peters
- Siteman Cancer Center - West County, Creve Coeur
- Siteman Cancer Center - North County, Florissant
- og 6 flere
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07227012A Study Evaluating a New Radiation Treatment Workflow (NGDS)
- Siteman Cancer Center Washington University, St Louis
Rekrutterer
Alder 21 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07824583Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, St Louis
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06921785Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Washington University School of Medicine, St Louis
RekruttererFase 1/2
12 Months – 30 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04851119FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Washington University School of Medicine, St Louis
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT05919264Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- Washington University School of Medicine, St Louis
- og 2 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT07166406First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
- Research Site, St Louis
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 13. aug. 2026 · NCT06795022IDOV-Immune for Advanced Solid Tumors
- Washington University School of Medicine, St Louis
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 5. aug. 2026 · NCT06910657A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Mosaic Life Care at Saint Joseph - Medical Center, Saint Joseph
RekruttererFase 2
Alder 8 og eldre · Alle kjønn · Oppdatert 27. jul. 2026 · NCT05503797Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- St. Louis VA Medical Center John Cochran Division, St. Louis, MO, St Louis
Rekrutterer
Alder 18 til 75 · Alle kjønn · Oppdatert 17. jun. 2026 · NCT05486572A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Washington University in St. Louis, St Louis
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 27. apr. 2026 · NCT05440708SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Kansas City
- Massive Bio SYNERGY-AI site, St Louis
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.